Chemed Corp. (NYSE:CHE) to Release Earnings on Tuesday

Chemed Corp. (NYSE:CHE) will release its earnings data after the market closes on Tuesday, July 25th. Analysts expect Chemed Corp. to post earnings of $1.89 per share for the quarter. Chemed Corp. has set its FY17 guidance at $7.80-$8.00 EPS.

Chemed Corp. (NYSE:CHE) last announced its quarterly earnings data on Wednesday, April 26th. The company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.04. The company had revenue of $405.90 million for the quarter, compared to analysts’ expectations of $399.75 million. Chemed Corp. had a net margin of 7.14% and a return on equity of 24.62%. Chemed Corp.’s revenue was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.62 EPS. On average, analysts expect Chemed Corp. to post $7.83 EPS for the current fiscal year and $8.51 EPS for the next fiscal year.

Chemed Corp. (CHE) opened at 205.75 on Tuesday. The firm has a 50-day moving average of $204.60 and a 200 day moving average of $183.85. The firm has a market capitalization of $3.31 billion, a PE ratio of 30.19 and a beta of 1.15. Chemed Corp. has a 52 week low of $130.05 and a 52 week high of $216.01.

In other Chemed Corp. news, Director Donald E. Saunders sold 400 shares of the firm’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $204.85, for a total value of $81,940.00. Following the sale, the director now directly owns 9,886 shares in the company, valued at $2,025,147.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director George J. Walsh III bought 1,000 shares of the business’s stock in a transaction on Monday, June 26th. The stock was bought at an average price of $204.56 per share, for a total transaction of $204,560.00. Following the completion of the purchase, the director now directly owns 7,908 shares of the company’s stock, valued at approximately $1,617,660.48. The disclosure for this purchase can be found here. Insiders sold 5,400 shares of company stock worth $1,104,850 over the last quarter. 5.32% of the stock is currently owned by company insiders.

WARNING: “Chemed Corp. (NYSE:CHE) to Release Earnings on Tuesday” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://transcriptdaily.com/2017/07/18/chemed-corp-nyseche-to-release-earnings-on-tuesday.html.

A number of research firms have issued reports on CHE. BidaskClub cut Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 22nd. Zacks Investment Research cut Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $208.00 target price on shares of Chemed Corp. in a research note on Wednesday, July 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Chemed Corp. currently has an average rating of “Hold” and a consensus price target of $186.00.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Earnings History for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply